Enzyme activities in tissue of human benign prostatic
hyperplasia
Study
TITLE
Enzyme activities in tissue of human
benign prostatic hyperplasia after three months' treatment with the Sabal
serrulata extract IDS 89 (Strogen) or placebo.
AUTHOR
Weisser H; Behnke B; Helpap B; Bach D;
Krieg M
ORGANISATION
Institute of Clinical Chemistry,
Transfusion and Laboratory Medicine, University Clinic Bergmannsheil, Bochum,
Germany.
SOURCE
Eur Urol 1997; 31 (1):
97-101
LANGUAGE OF
ORIGIN
English
ABSTRACT
OBJECTIVE: The mechanism of action of plant
extracts used for the medical treatment of human benign prostatic hyperplasia
(BPH) is still unknown. In this prospective, randomized, double-blind trial, we
investigated the possible influence of the Sabal serrulata extract IDS 89
(Strogen) on epithelial and stromal enzyme activities of BPH tissue.
METHODS: 18 patients with BPH were
randomly assigned to receive 3 x 2 capsules Strogen uno (320 mg/capsule) (n=8)
or placebo (n=10) daily for 3 months. The activity (Vmax and Km) of 5
alpha-reductase. 3 alpha-HSORred, 3 beta-HSORred, and creatine kinase was
determined in mechanically separated epithelium and stroma of human BPH.
RESULTS: The multivariate correlation analysis revealed a positive correlation
between therapy and the following enzyme alterations: (1) In epithelium, the
substrate affinity of the 5 alpha-reductase decreased slightly (increase of Km
value). (2) In stroma, the Vmax value of the 3 alpha-HSORred increased
statistically distinctly, leading to a moderate increase of Vmax/Km. (3) In
stroma, the Vmax value of the 3 beta-HSORred increased moderately, but not
statistically significant. (4) In stroma, the Vmax value of creatine kinase
increased significantly, leading to a statistically distinct increase of
Vmax/Km. CONCLUSION: This double-blind, placebo-controlled clinical trial with
the S. serrulata extract IDS 89 revealed significant biochemical changes at the
cellular level of BPH tissue. However, the alterations are merely moderate,
their biochemical causes and consequences regarding the pathophysiology of BPH
rather uncertain. Therefore, more studies are needed before plant extracts like
IDS 89 become valid candidates likewise synthetic substances already used for
medical treatment of human BPH. (AUTHOR)
MJTR:
Enzyme Inhibitors TU. Fatty Acids TU. Phytosterols TU. Plant Extracts TU.
Prostatic Hyperplasia DT. Prostatic Hyperplasia EN.
MNTR:
Aged. Creatine Kinase AI. Creatine Kinase ME. Double-Blind Method. Human.
Male. Middle Age. Prospective Studies. Prostate EN. Testosterone
5-alpha-Reductase AI. Testosterone 5-alpha-Reductase ME. Time Factors.
3-Hydroxysteroid Dehydrogenases AI. 3-Hydroxysteroid Dehydrogenases ME. CLINICAL
TRIAL. JOURNAL ARTICLE. RANDOMIZED CONTROLLED TRIAL
RNUM: EC 1.1.- (3-Hydroxysteroid
Dehydrogenases); EC 1.3.99.5 (Testosterone 5-alpha-Reductase); EC 2.7.3.2
(Creatine Kinase); 0 (Enzyme Inhibitors); 0 (Fatty Acids); 0 (IDS 89 Sabal
serrulata extract); 0 (Phytosterols); 0 (Plant Extracts) PAGE 6 National Library
of Medicine MEDLINE Database
GEOT: SWITZERLAND
IDEN: ISSN: 0302-2838. JOURNAL-CODE:
ENM. ENTRY-DATE: 970603. JOURNAL-SUBSET: M. IM-DATE: 9708.
ACCE: 97184773
